CJC 1295 refers to a tetrasubstituted peptide hormone which contains 30 amino acids. The synthetic version of this chemical was developed by the Canadian biotechnology specialty company ConjuChem, which also acts as the main distributor for this chemical for those that are interested in using it in a research setting.
One of the main advantages researchers have found in using CJC 1295 over using traditional applications of growth hormone releasing hormone is that CJC 1295 is capable of bioconjugating with the serum albumin within an animal’s body.
This has significantly increased the working window and the half-life for this product when it is applied to live animal tissues. This alteration was accomplished by creating protecting groups made up of amino acids, developed from growth hormone producing hormone which would normally be susceptible to segregation from enzymes.
Bioconjucation of CJC 1295
The main benefit of using CJC 1295 over the naturally occurring growth hormone releasing hormone in the body is the extended half-life of the substance which allows it to have a greater impact on the tissues it interacts with.
- The main reason that CJC 1295 is capable of lengthening its half-life when it reaches the active agent revolves around the biological process of bio-conjugation.
- The bioconjugation technology is relatively new, allowing scientists to harvest a reactive group and allow it to bond with a given peptide. The attachment to this peptide allows for a reaction that creates a nucleophilic unit. This is typically a partial molecule which can be found within an animal’s bloodstream and then tracked as research continues.
- The bioconjugation reaction is particularly valuable when working with peptides because this allows the bond to become more stable. Many synthesized chemicals have a very short half-life or do not break down the same way the natural forms of these chemicals might which can make for less than reliable test results that will impact animal test subjects in ways that could be ineffective or dangerous.
CJC 1295 in particular has a high attraction to the chemical albumin which is a globular protein that is water soluble. This bond prohibits the peptide from naturally degrading when it is exposed to other chemicals and fluids within an animal’s body which increases its overall shelf-life. In addition to this, clinical research on animal test subjects has currently shown consistently that CJC 1295 does not show signs of DPP-IV segregation when it is introduced into an animal.
Prolonged Stimulation of Growth Hormone
Using growth-hormone releasing hormone in a specific manner is designed to increase an animal’s secretion of growth hormone but this is limited, due to the natural chemical’s limited duration of action.
- The objective of ongoing studies is to examine the pharmacodynamics effects and pharmacokinetic profile as well as the safety of using CJC 1295 as a long acting growth hormone releasing hormone. Initially this study was performed on two investigational sites on healthy adult animal test subjects at a variety of age ranges.
- These test subjects were exposed to CJC 1295 or a placebo which was both applied in 1-4 different application sizes during the first study. During the second study applications were given in biweekly or 2-3 day doses. The main outcome was to note the peak concentrations of IGF-1 and growth hormone and standard pharmacokinetic parameters were used to measure CJC 1295 within the animal’s system.
- Following a single application of CJC 1295 via injection there were sustained results which showed increases in IGF-1 and growth hormone, though these results were clearly application dependent. The animals appeared to tolerate the chemical well and it appeared to be safe for use, particularly at 30-60 ug/kg applications. There was some evidence that CJC 1295 could provide a cumulative effect after multiple applications were administered.
The use of CJC 1295 in developing animals or those in puberty has generally been accepted as a potential practice. Given the need for an unlimited supply of growth hormone in those that are not developing properly, it is believed that there is more potential use for this chemical in the developing market: though more research into the safety of this chemical must be performed to guarantee this use.
CJC 1295 is a very unique chemical with specific properties which differentiate it from other growth hormone releasing hormone on the market for research study today. Given the specific nature of these compounds it is important to work with companies that are approved or partners with ConjuChem, to ensure that they are using the patented formula to create research-grade samples that are suitable for application in live animal test subjects. This will ensure accurate research that can be replicated by peers in the field.
http://www.maximpeptide.com/peptides/ (several versions of Cjc-1295)